| 证券代码：688131 | 证券简称：皓元医药 | 公告编号：2025-127 | | --- | --- | --- | | 转债代码：118051 | 转债简称：皓元转债 | | 上海皓元医药股份有限公司 关于公司及子公司向银行申请 2026 年度综合授信 额度并由公司为子公司银行授信提供担保的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 对外担保逾期的累计金额（万元） | | 不适用 | | | --- | --- | --- | --- | | 截至 年 月 日上市公司 2025 12 | 11 | | | | 及其控股子公司对外担保总额（万 | | 73,242.19 | | | 元） | | | | | 对外担保总额占上市公司最近一 期经审计净资产的比例（%） | | 25.45 | | | 特别风险提示（如有请勾选） | | | □对外担保总额（含本次）超过上市公司最近一期 | | | | 经审计净资产 | 50% | | | | | □对外担保总额（含本次）超过上市公司最近一期 ...

| 证券代码：688131 | 证券简称：皓元医药 | 公告编号：2025-126 | | --- | --- | --- | | 转债代码：118051 | 转债简称：皓元转债 | | 上海皓元医药股份有限公司 关于 2026 年度日常关联交易预计的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、日常关联交易基本情况 （一）日常关联交易履行的审议程序 公司于2025年12月12日召开2025年第五次董事会独立董事专门会议，审议 通过了《关于公司2026年度日常关联交易预计的议案》，独立董事认为：公司 预计2026年度与关联方发生的日常关联交易均是为了满足日常生产经营的需要， 属于正常商业行为，遵循市场公允定价原则，且充分利用关联方拥有的资源为 公司的生产经营服务，有利于交易双方获得合理的经济效益；2026年度预计的 日常关联交易金额是公司根据2025年度生产经营情况合理得出，定价公允合理， 未发现损害公司及其他股东利益，不会对公司独立性产生影响，公司亦不会因 关联交易而对关联方形成依赖。全体独立 ...

Core Viewpoint - The company plans to issue convertible bonds to raise a net amount of 812 million yuan in 2024, aiming to enhance the efficiency of fund utilization [1] Group 1: Fundraising and Management - The company intends to raise 812 million yuan through the issuance of convertible bonds to unspecified investors [1] - To improve fund utilization efficiency, the company plans to use up to 500 million yuan of idle raised funds for cash management, investing in principal-protected financial products [1] - The cash management period will be effective for 12 months starting from December 12, 2025, with funds being available for rolling use [1] Group 2: Governance and Compliance - The board of directors has approved the cash management plan, which does not require submission for shareholder meeting approval [1] - The company previously encountered an issue where an employee mistakenly exceeded the authorized limit by 49 million yuan for cash management, but this excess has now been redeemed [1] - The sponsoring institution has no objections to the proposed cash management plan [1]

每经头条（nbdtoutiao）——实施城乡居民增收计划、降准降息等工具灵活高效运用、增加普通高中学 位……深度解读中央经济工作会议 每经AI快讯，皓元医药（SH 688131，收盘价：73.5元）12月12日晚间发布公告称，截至2025年12月11 日，公司及子公司对外担保总额为人民币约7.32亿元（含本次担保），全部为公司对全资或控股子公司 提供的担保总额，占公司2024年度经审计净资产及总资产的比例分别为25.45%、13.3%。 2024年1至12月份，皓元医药的营业收入构成为：研究和试验发展行业占比99.27%，其他业务占比 0.73%。 截至发稿，皓元医药市值为156亿元。 （记者 曾健辉） ...

Core Viewpoint - The medical services sector experienced a decline of 2.05% on December 2, with Yinosh leading the drop. The Shanghai Composite Index closed at 3897.71, down 0.42%, while the Shenzhen Component Index closed at 13056.7, down 0.68% [1]. Group 1: Market Performance - The medical services sector saw significant individual stock movements, with ST Zhongzhu closing at 2.95, up 3.51%, and Yinosh closing at 41.58, down 7.27% [1][2]. - The total net outflow of main funds in the medical services sector was 9.53 billion yuan, while retail investors saw a net inflow of 6.87 billion yuan [2][3]. Group 2: Individual Stock Analysis - ST Zhongzhu had a trading volume of 1.27 million hands and a transaction amount of 372 million yuan, while Yinosh had a trading volume of 19,500 hands and a transaction amount of 82.48 million yuan [1][2]. - The stock performance varied, with some stocks like Innovation Medical and Dean Diagnostics showing slight declines, while others like ST Zhongzhu showed gains [1][2]. Group 3: Fund Flow Analysis - Main funds showed a net inflow in stocks like Innovation Medical (63.01 million yuan) and Dean Diagnostics (20.61 million yuan), while there were net outflows in several other stocks [3]. - Retail investors contributed to the net inflow in stocks like Innovation Medical and Dean Diagnostics, despite overall sector outflows [3].

Core Viewpoint - Haoyuan Pharmaceutical's stock has shown significant growth this year, with a year-to-date increase of 116.75%, indicating strong market performance and investor interest [1][2]. Company Overview - Haoyuan Pharmaceutical, established on September 30, 2006, and listed on June 8, 2021, is located in Shanghai and specializes in the discovery of small molecule drugs, including the development of molecular building blocks and tool compounds [2]. - The company's main business revenue composition includes molecular building blocks and tool compounds (68.97%), with product sales contributing 63.42%, raw materials and intermediates at 30.46%, and technical services at 5.55% [2]. Financial Performance - For the period from January to September 2025, Haoyuan Pharmaceutical achieved a revenue of 2.059 billion yuan, representing a year-on-year growth of 27.18%, while the net profit attributable to shareholders was 237 million yuan, up 65.09% year-on-year [2]. - The company has distributed a total of 160 million yuan in dividends since its A-share listing, with 120 million yuan distributed over the past three years [3]. Shareholder Information - As of September 30, 2025, the number of shareholders for Haoyuan Pharmaceutical was 12,000, a decrease of 6.34% from the previous period, with an average of 17,647 circulating shares per shareholder, an increase of 6.77% [2]. - Notable institutional shareholders include Hong Kong Central Clearing Limited, which holds 8.6068 million shares, and several funds that have increased their holdings [3].

Market Overview - On December 1, the medical services sector rose by 0.68% compared to the previous trading day, with ST Zhongzhu leading the gains [1] - The Shanghai Composite Index closed at 3914.01, up 0.65%, while the Shenzhen Component Index closed at 13146.72, up 1.25% [1] Top Gainers in Medical Services Sector - ST Zhongzhu (600568) closed at 2.85, up 5.17% with a trading volume of 230,800 shares and a turnover of 64.91 million yuan [1] - Haoyuan Pharmaceutical (688131) closed at 78.45, up 3.21% with a trading volume of 30,400 shares and a turnover of 238 million yuan [1] - Kanglong Chemical (300759) closed at 29.66, up 2.45% with a trading volume of 189,900 shares and a turnover of 563 million yuan [1] Top Losers in Medical Services Sector - Bid Pharma (688073) closed at 69.33, down 4.70% with a trading volume of 10,800 shares and a turnover of 75.39 million yuan [2] - Chengda Pharmaceutical (301201) closed at 45.90, down 4.26% with a trading volume of 116,700 shares [2] - Yaokang Bio (688046) closed at 16.40, down 4.21% with a trading volume of 36,600 shares and a turnover of 60.80 million yuan [2] Capital Flow Analysis - The medical services sector experienced a net outflow of 152 million yuan from institutional investors, while retail investors saw a net inflow of 88.82 million yuan [2] - Notable stocks with significant capital inflow include Innovation Medical (002173) with a net inflow of 29.99 million yuan from institutional investors [3] - Conversely, stocks like Bid Pharma (688073) faced a net outflow of 63.70 million yuan from institutional investors [3]

Core Insights - The article discusses the growth and strategic direction of Haoyuan Pharmaceutical, a CRO company in China, emphasizing its commitment to long-term development and innovation in the biopharmaceutical industry [2][8]. Company Overview - Haoyuan Pharmaceutical was founded in 2006 with an initial investment of 1.5 million yuan, aiming to contribute to China's transition from a "big pharmaceutical country" to a "strong pharmaceutical country" [2]. - The company has developed a comprehensive service chain covering "starting materials - intermediates - active pharmaceutical ingredients - formulations" [2]. Business Model - The company operates with a dual business model, focusing on both front-end life science reagents and back-end CDMO services, enhancing its competitive edge [3][4]. - As of September 2025, Haoyuan has accumulated over 152,000 types of life science reagents, including more than 96,000 molecular building blocks [3]. Market Strategy - The company aims to provide a full-process service from candidate molecules to commercial production, significantly reducing quality and time costs associated with segmented production [4]. - Haoyuan has established a diverse Payload-Linker sample library and has completed FDA sec-DMF filings for 15 ADC-related small molecule products [4]. Global Expansion - Since 2015, Haoyuan has initiated a global strategy for its life science reagent business, establishing an international business development team and logistics systems, currently serving over 13,000 global customers [5]. - The company reported overseas revenue of 862 million yuan in 2024, a year-on-year increase of 24.7%, and 560 million yuan in the first half of 2025, a growth of approximately 40% [6]. Innovation and Technology - Haoyuan is actively exploring the application of AI technology in drug development, aiming to shorten research cycles and enhance the quality and efficiency of compound screening [9]. - The company is focused on cutting-edge fields such as small molecules, ADC/XDC, peptides, and small nucleic acids, with the goal of making drug development more efficient and accessible [9].

Market Overview - The medical services sector increased by 0.56% on November 25, with ST Zhongzhu leading the gains [1] - The Shanghai Composite Index closed at 3870.02, up 0.87%, while the Shenzhen Component Index closed at 12777.31, up 1.53% [1] Top Gainers in Medical Services - ST Zhongzhu (600568) closed at 2.57, up 4.90% with a trading volume of 53,900 shares and a turnover of 13.85 million yuan [1] - Chengda Pharmaceutical (301201) closed at 47.78, up 2.97% with a trading volume of 112,700 shares and a turnover of 540 million yuan [1] - Boji Pharmaceutical (300404) closed at 10.10, up 2.75% with a trading volume of 108,600 shares and a turnover of 10.9 million yuan [1] Top Losers in Medical Services - Jiuzhou Pharmaceutical (603456) closed at 18.75, down 0.85% with a trading volume of 181,100 shares and a turnover of 343 million yuan [2] - Tongce Medical (600763) closed at 41.95, down 0.66% with a trading volume of 49,600 shares and a turnover of 210 million yuan [2] - Yingkang Life (300143) closed at 10.12, down 0.49% with a trading volume of 44,700 shares and a turnover of 4.56 million yuan [2] Capital Flow Analysis - The medical services sector experienced a net outflow of 113 million yuan from institutional investors, while retail investors saw a net inflow of 30.37 million yuan [2][3] - Major stocks like WuXi AppTec (603259) had a net inflow of 67.13 million yuan from institutional investors, while Sunshine Nuohua (688621) saw a net outflow of 2.29 million yuan from retail investors [3] Summary of Individual Stock Performance - Sunshine Nuohua (688621) had a net inflow of 38.24 million yuan from institutional investors, but a net outflow of 3.59 million yuan from retail investors [3] - Chengda Pharmaceutical (301201) also saw a significant net inflow of 36.45 million yuan from institutional investors, with a net outflow of 13.58 million yuan from retail investors [3] - New Mileage (002219) had a net inflow of 14.15 million yuan from institutional investors, while retail investors experienced a net outflow of 6.70 million yuan [3]

Core Viewpoint - The article discusses the performance of the Zhongzheng 1000 ETF Enhanced (561280), highlighting its recent market movements and key holdings [1]. Group 1: Fund Performance - The Zhongzheng 1000 ETF Enhanced (561280) opened with a gain of 0.56%, priced at 1.443 yuan [1]. - Since its establishment on August 31, 2023, the fund has achieved a return of 42.77%, while its return over the past month has been -4.93% [1]. Group 2: Key Holdings - Major stocks in the fund include: - Boqian New Materials, up 0.68% - Haoyuan Pharmaceutical, up 0.88% - Yingjixin, up 1.01% - Caixun Co., up 0.51% - Jinma Amusement, up 1.22% - Panjiang Co., up 0.42% - Jindawei, up 1.02% - Yiyuan Communication, up 0.69% - Minxin Co., up 0.50% - Nami Technology, up 0.48% [1].